Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Massachusetts General Hospital, Boston, Mass, United States

Survival: N/R
Toxicity Grade: 3
Treatments: Biologic therapy
Country: United States
City/State/Province: Boston, Mass
Hospital: Massachusetts General Hospital
Journal: Link
Date: 6/2006

Patients: This phase II study involved 44 men with metastatic prostate cancer. The men were divided into two groups of 22 patients, group 1 and group 2. The mean age of group 1 was 75.6 years (ranging from 54-88) and group 2 was 72.7 (ranging from 56-88).

Treatment: Group 1 received astrasentan alone, and group 2 received a combination of a biological agent astrasentan (a selective endothelin-A receptor antagonist) and zolendronic acid. After 12 weeks, the men in both groups that were still in the study received the combination therapy.

Toxicity: One man in each group experienced grade 3 edema and dyspnea and stopped therapy, after which their symptoms improved. Two serious adverse events occurred (myocardial infarction and gastrointestinal bleeding) but were considered unrelated to the treatment. The occurrence of myalgias, bone pain, and fever were more common in group 2, while edema was more common in group 1.

Results: This therapy had minimal clinical efficacy with no objective responses. Most patients had disease progression when examined 12 weeks after therapy. One patient receiving astrasentan alone (group 1) had an improvement in his prostrate-specific antigen response.

Support: This study was supported in part by Abbot Laboratories, which provided the astrasentan.

Correspondence: Dr. M. Dror Michaelson

E-mail to a Friend Email Physician More Information